AR092108A1 - Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn - Google Patents
Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smnInfo
- Publication number
- AR092108A1 AR092108A1 ARP130102863A ARP130102863A AR092108A1 AR 092108 A1 AR092108 A1 AR 092108A1 AR P130102863 A ARP130102863 A AR P130102863A AR P130102863 A ARP130102863 A AR P130102863A AR 092108 A1 AR092108 A1 AR 092108A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- independently selected
- alkoxy
- mono
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Abstract
El presente proporciona una combinación de agentes farmacológicamente activos y una composición farmacéutica. Reivindicación 1: Un compuesto o sal del mismo según la fórmula (1), A es 2-hidroxi-fenilo que se sustituye por 0, 1, 2, ó 3 sustituyentes seleccionados independientemente a partir de alquilo C₁₋₄, en donde 2 grupos alquilo C₁₋₄ pueden combinarse con los átomos a los que están unidos para formar un anillo de 5 - 6 miembros y se sustituye por 0 ó 1 sustituyentes seleccionados a partir de oxo, oxima e hidroxilo, haloalquilo C₁₋₄, dihaloalquilo C₁₋₄, trihaloalquilo C₁₋₄, alcoxilo C₁₋₄, alcoxi C₁₋₄-cicloalquilo C₃₋₇, haloalcoxilo C₁₋₄, dihaloalcoxilo C₁₋₄, trihaloalcoxilo C₁₋₄, hidroxilo, ciano, halógeno, amino, mono- y di-alquil C₁₋₄amino, heteroarilo, alquilo C₁₋₄ sustituido por hidroxilo, alcoxilo C₁₋₄ sustituido por arilo, amino, -C(O)NH-alquilo C₁₋₄-heteroarilo, -NHC(O)-heteroarilo-alquilo C₁₋₄-, alquilo C₁₋₄C₍O₎NH₋ₕₑₜₑʳₒₐʳⁱₗₒ, ₐₗqᵘⁱₗₒ C₁₋₄NHC(O)-heteroarilo, cicloalquilo de 3 - 7 miembros, cicloalquenilo de 5 - 7 miembros o heterociclo de 5, 6 ó 9 miembros que contiene 1 ó 2 heteroátomos independientemente seleccionados a partir de S, O y N, en donde heteroarilo tiene 5, 6 ó 9 átomos de anillo, 1, 2 ó 3 heteroátomos de anillo seleccionados a partir de N, O y S y sustituido por 0, 1, ó 2 sustituyentes seleccionados independientemente a partir de oxo, hidroxilo, nitro, halógeno, alquilo C₁₋₄, alquenilo C₁₋₄, alcoxilo C₁₋₄, cicloalquilo C₃₋₇, alquil C₁₋₄-OH, trihaloalquilo C₁₋₄, mono- y di-alquil C₁₋₄amino, -C(O)NH₂, -NH₂, -NO₂, hidroxi-alquil C₁₋₄amino, hidroxialquilo C₁₋₄, heterocicloalquilo C₁₋₄ de 4 - 7 miembros, aminoalquilo C₁₋₄ y mono- y di-alquil C₁₋₄aminoalquilo C₁₋₄; o A es 2-naftilo opcionalmente sustituido en la posición 3 por hidroxilo y adicionalmente sustituido por 0, 1, ó 2 sustituyentes seleccionados a partir de hidroxilo, ciano, halógeno, alquilo C₁₋₄, alquenilo C₂₋₄, alcoxilo C₁₋₅, en donde el alcoxilo no es sustituido o se sustituye por hidroxilo, alcoxilo C₁₋₄, amino, N(H)C(O)alquilo C₁₋₄, N(H)C(O)₂alquilo C₁₋₄, alquileno heterociclo de 4 a 7 miembros, heterociclo de 4 a 7 miembros y mono- y di-alquil C₁₋₄amino; o A es heteroarilo de 6 miembros que tiene 1 - 3 átomos de nitrógeno de anillo, tal heteroarilo de 6 miembros es sustituido por fenilo o un heteroarilo que tiene 5 ó 6 átomos de anillo, 1 ó 2 heteroátomos de anillo seleccionados independientemente a partir de N, O y S y sustituido por 0, 1, ó 2 sustituyentes seleccionados independientemente a partir de alquilo C₁₋₄, mono- y di-alquil C₁₋₄amino, hidroxi-alquil C₁₋₄amino, hidroxialquilo C₁₋₄, aminoalquilo C₁₋₄ y mono- y di-alquil C₁₋₄amino-alquilo C₁₋₄; o A es heteroarilo bicíclico que tiene 9 a 10 átomos de anillo, y 1, 2, ó 3 heteroátomos de anillo seleccionados independientemente a partir de N, O ó S, tal heteroarilo bicíclico se sustituye por 0, 1, ó 2 sustituyentes seleccionados independientemente a partir de ciano, halógeno, hidroxilo, alquilo C₁₋₄, alquenilo C₂₋₄, alquinilo C₂₋₄, alcoxilo C₁₋₄ y alcoxilo C₁₋₄ sustituido por hidroxilo, alcoxilo C₁₋₄, amino y mono- y di-alquil C₁₋₄amino; o A es heteroarilo tricíclico que tiene 12 ó 13 átomos de anillo, y 1, 2, ó 3 heteroátomos de anillo seleccionados independientemente a partir de N, O ó S, tal heteroarilo tricíclico se sustituye por 0, 1, ó 2 sustituyentes seleccionados independientemente a partir de ciano, halógeno, hidroxilo, alquilo C₁₋₄, alquenilo C₂₋₄, alquinilo C₂₋₄, alcoxilo C₁₋₄, alcoxilo C₁₋₄ sustituido por hidroxilo, alcoxilo C₁₋₄, amino, mono- y di-alquil C₁₋₄amino y heteroarilo, en donde dicho heteroarilo tiene 5, 6 ó 9 átomos de anillo, 1, 2 ó 3 heteroátomos de anillo seleccionados a partir de N, O y S y sustituido por 0, 1, ó 2 sustituyentes seleccionados independientemente a partir de oxo, hidroxilo, nitro, halógeno, alquilo C₁₋₄, alquenilo C₁₋₄, alcoxilo C₁₋₄, cicloalquilo C₃₋₇, alquil C₁₋₄-OH, trihaloalquilo C₁₋₄, mono- y di-alquil C₁₋₄amino, -C(O)NH₂, -NH₂, -NO₂, hidroxi-alquil C₁₋₄amino, hidroxialquilo C₁₋₄, heterocicloalquilo C₁₋₄ de 4 - 7 miembros, aminoalquilo C₁₋₄ y mono- y di-alquil C₁₋₄aminoalquilo C₁₋₄; B es un grupo de la fórmula (2), en donde m, n y p son independientemente seleccionados a partir de 0 ó 1; R, R¹, R², R³, y R⁴ son independientemente seleccionados a partir del grupo que consta de hidrógeno, alquilo C₁₋₄, tal alquilo se sustituye opcionalmente por hidroxilo, amino o mono- y di-alquil C₁₋₄amino; R⁵ y R⁶ son independientemente seleccionados a partir de hidrógeno y flúor; o R y R³, tomados en combinación forman un anillo heterocíclico condensado de 5 ó 6 miembros que tiene 0 ó 1 heteroátomos adicionales de anillo seleccionados a partir de N, O ó S; R¹ y R³, tomados en combinación forman un grupo alquileno C₁₋₃; R¹ y R⁵, tomados en combinación forman un grupo alquileno C₁₋₃; R³ y R⁴, tomados en combinación con el átomo de carbono al que están unidos, forman un cicloalquilo C₃₋₆ espirocíclico; X es CRARB, O, NR⁷ o un enlace; R⁷ es hidrógeno, o alquilo C₁₋₄; RA y RB son independientemente seleccionados a partir de hidrógeno y alquilo C₁₋₄, o RA y RB, tomados en combinación, forman un grupo alquileno C₂₋₅ divalente; Z es CR⁸ o N; cuando Z es N, X es un enlace; R⁸ es hidrógeno o tomados en combinación con R⁶ forman un enlace doble; o B es un grupo de la fórmula (3), en donde p y q son independientemente seleccionados a partir del grupo que consta de 0, 1, y 2; R⁹ y R¹³ son independientemente seleccionados a partir de hidrógeno y alquilo C₁₋₄; R¹⁰ y R¹⁴ son independientemente seleccionados a partir de hidrógeno, amino, mono- y di-alquil C₁₋₄amino y alquilo C₁₋₄, tal alquilo se sustituye opcionalmente por hidroxilo, amino o mono- y di-alquil C₁₋₄amino; R¹¹ es hidrógeno, alquilo C₁₋₄, amino o mono- y di-alquil C₁₋₄amino; R¹² es hidrógeno o alquilo C₁₋₄; o R⁹ y R¹¹, tomados en combinación forman un azaciclo saturado que tiene 4 a 7 átomos de anillo, el cual es opcionalmente sustituido por 1 - 3 grupos alquilo C₁₋₄; o R¹¹ y R¹², tomados en combinación forman un azaciclo saturado que tiene 4 a 7 átomos de anillo, el cual es opcionalmente sustituido por 1 - 3 grupos alquilo C₁₋₄.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261682448P | 2012-08-13 | 2012-08-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR092108A1 true AR092108A1 (es) | 2015-03-25 |
Family
ID=49029227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130102863A AR092108A1 (es) | 2012-08-13 | 2013-08-13 | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn |
Country Status (41)
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9403815B2 (en) | 2010-06-24 | 2016-08-02 | The Regents Of The University Of California | Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms |
MY174339A (en) * | 2012-08-13 | 2020-04-09 | Novartis Ag | 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions |
US9938263B2 (en) | 2013-03-12 | 2018-04-10 | The General Hospital Corporation | Gamma-secretase modulators |
KR102318727B1 (ko) * | 2013-07-31 | 2021-10-28 | 노파르티스 아게 | 1,4-이치환된 피리다진 유사체 및 smn-결핍-관련 상태를 치료하기 위한 그의 용도 |
GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
WO2016054615A2 (en) | 2014-10-03 | 2016-04-07 | Cold Spring Harbor Laboratory | Targeted augmentation of nuclear gene output |
AU2015338946B2 (en) * | 2014-10-31 | 2020-06-11 | The General Hospital Corporation | Potent gamma-secretase modulators |
WO2016128343A1 (en) * | 2015-02-09 | 2016-08-18 | F. Hoffmann-La Roche Ag | Compounds for the treatment of cancer |
EP3053577A1 (en) | 2015-02-09 | 2016-08-10 | F. Hoffmann-La Roche AG | Compounds for the treatment of cancer |
WO2017060731A1 (en) | 2015-10-09 | 2017-04-13 | University Of Southampton | Modulation of gene expression and screening for deregulated protein expression |
LT3386511T (lt) | 2015-12-10 | 2021-08-25 | Ptc Therapeutics, Inc. | Hantingtono ligos gydymo būdai |
EP3390636B1 (en) | 2015-12-14 | 2021-05-19 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of dravet syndrome |
US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
BR112018017077A2 (pt) * | 2016-02-23 | 2018-12-26 | Univ Indiana Res & Tech Corp | terapias de combinação para tratamento de atrofia muscular espinhal |
MX2019014514A (es) | 2017-06-05 | 2020-07-20 | Ptc Therapeutics Inc | Compuestos para tratar la enfermedad de huntington. |
EP3638318A4 (en) | 2017-06-14 | 2021-03-17 | PTC Therapeutics, Inc. | METHOD OF MODULATION OF RNA SPLICING |
CA3067591A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Methods for treating huntington's disease |
EP3645121A4 (en) | 2017-06-28 | 2021-03-17 | PTC Therapeutics, Inc. | HUNTINGTON'S DISEASE TREATMENT METHODS |
WO2019028440A1 (en) | 2017-08-04 | 2019-02-07 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATING SPLICING |
CA3073515A1 (en) | 2017-08-25 | 2019-02-28 | Stoke Therapeutics, Inc. | Antisense oligomers for treatment of conditions and diseases |
AU2018388404B2 (en) | 2017-12-22 | 2023-11-02 | HiberCell Inc. | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
EA202092001A1 (ru) | 2018-03-27 | 2021-01-29 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Соединения для лечения болезни гентингтона |
EP3781564B1 (en) * | 2018-04-10 | 2023-08-23 | Skyhawk Therapeutics, Inc. | Pyridazine derivatives for the treatment of cancer |
US11858941B2 (en) | 2018-06-27 | 2024-01-02 | Ptc Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating Huntington's disease |
WO2020005882A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
US20210179586A1 (en) | 2018-09-07 | 2021-06-17 | Teva Pharmaceuticals International Gmbh | Solid state forms of branaplam and their preparation |
BR112021011744A2 (pt) | 2018-12-21 | 2021-08-31 | Novartis Ag | Formulações orais de branaplam |
KR20210135240A (ko) * | 2019-02-05 | 2021-11-12 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
WO2020163405A1 (en) * | 2019-02-05 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
JP2022520051A (ja) * | 2019-02-05 | 2022-03-28 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
KR20210135507A (ko) | 2019-02-06 | 2021-11-15 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
KR20210135511A (ko) * | 2019-02-06 | 2021-11-15 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
WO2020190793A1 (en) * | 2019-03-15 | 2020-09-24 | Skyhawk Therapeutics, Inc. | Compositions and methods for correction of aberrant splicing |
JP2022533120A (ja) * | 2019-05-13 | 2022-07-21 | ピーティーシー セラピューティクス, インコーポレイテッド | ハンチントン病を処置するための化合物 |
AR119731A1 (es) * | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
KR20220035937A (ko) | 2019-07-25 | 2022-03-22 | 노파르티스 아게 | 조절 가능한 발현 시스템 |
CA3156848A1 (en) | 2019-11-01 | 2021-05-06 | Novartis Ag | The use of a splicing modulator for a treatment slowing progression of huntington's disease |
EP4110775A1 (en) | 2020-02-28 | 2023-01-04 | Remix Therapeutics Inc. | Thiophenyl derivatives useful for modulating nucleic acid splicing |
JP2023515621A (ja) | 2020-02-28 | 2023-04-13 | リミックス セラピューティクス インコーポレイテッド | 複素環アミド及びスプライシングを調節するためのその使用 |
JP2023515618A (ja) | 2020-02-28 | 2023-04-13 | リミックス セラピューティクス インコーポレイテッド | 核酸スプライシングを調節するためのピリダジン誘導体 |
AU2021228285A1 (en) | 2020-02-28 | 2022-09-29 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
TW202208344A (zh) | 2020-04-08 | 2022-03-01 | 美商雷密克斯醫療公司 | 調節剪接之化合物及方法 |
BR112022020418A2 (pt) | 2020-04-08 | 2023-05-02 | Remix Therapeutics Inc | Compostos e métodos para modulação de splicing |
JP2023522177A (ja) * | 2020-04-09 | 2023-05-29 | ピーティーシー セラピューティクス, インコーポレイテッド | ハンチントン病を処置するための化合物 |
US20230287410A1 (en) | 2020-05-11 | 2023-09-14 | Stoke Therapeutics, Inc. | Opa1 antisense oligomers for treatment of conditions and diseases |
TW202208358A (zh) | 2020-05-13 | 2022-03-01 | 美商Chdi基金會股份有限公司 | 用於治療亨汀頓舞蹈症之htt調節劑 |
TW202216671A (zh) | 2020-06-25 | 2022-05-01 | 瑞士商諾華公司 | 1,4—二取代的嗒𠯤化合物之製造方法 |
MX2023000167A (es) | 2020-07-02 | 2023-05-03 | Remix Therapeutics Inc | Derivados de 5-[5-(piperidin-4-il)tieno[3,2-c]pirazol-2-il]indazol y compuestos relacionados como moduladores para el corte y empalme de ácidos nucleicos y para el tratamiento de enfermedades proliferativas. |
KR20230051168A (ko) | 2020-07-02 | 2023-04-17 | 레믹스 테라퓨틱스 인크. | 2-(인다졸-5-일)-6-(피페리딘-4-일)-1,7-나프티리딘 유도체, 및 핵산 스플라이싱의 조절제로서의 및 증식성 질환의 치료를 위한 관련 화합물 |
TW202304446A (zh) | 2021-03-29 | 2023-02-01 | 瑞士商諾華公司 | 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途 |
WO2023034833A1 (en) | 2021-08-30 | 2023-03-09 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
WO2023034836A1 (en) | 2021-08-30 | 2023-03-09 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
TW202328135A (zh) | 2021-08-30 | 2023-07-16 | 美商雷密克斯醫療公司 | 調節剪接之化合物及用途 |
WO2023034827A1 (en) | 2021-08-30 | 2023-03-09 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
WO2023034812A1 (en) | 2021-08-30 | 2023-03-09 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
WO2023064880A1 (en) | 2021-10-13 | 2023-04-20 | Remix Therapeutics Inc. | Compounds and methods for modulating nucleic acid splicing |
WO2023064879A1 (en) | 2021-10-13 | 2023-04-20 | Remix Therapeutics Inc. | Compounds and methods for modulating nucleic acid splicing |
WO2023092149A1 (en) * | 2021-11-22 | 2023-05-25 | Rgenta Therapeutics, Inc. | Heterocyclic substituted 1,3,4-thiadiazole and pyridazine compounds and methods of using the same |
TW202346305A (zh) | 2022-01-05 | 2023-12-01 | 美商雷密克斯醫療公司 | 用於調節剪切之化合物及方法 |
WO2023133217A1 (en) | 2022-01-05 | 2023-07-13 | Remix Therapeutics Inc. | 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases |
WO2023133229A2 (en) | 2022-01-05 | 2023-07-13 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
TWI778908B (zh) | 2022-01-21 | 2022-09-21 | 大里興業股份有限公司 | 具有改良減振結構之氣動衝擊工具 |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2427943C2 (de) | 1974-06-10 | 1984-08-02 | Dr. Karl Thomae Gmbh, 7950 Biberach | Benzimidazole, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
DE2516040C2 (de) | 1974-06-10 | 1984-12-20 | Dr. Karl Thomae Gmbh, 7950 Biberach | Benzimidazole, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
PT730590E (pt) | 1993-11-24 | 2001-05-31 | Du Pont Pharm Co | Derivados de isoxazolina e isoxazole como antagonistas dos reciptores do fibrinogenio |
CN1210274C (zh) | 2000-02-11 | 2005-07-13 | 沃泰克斯药物股份有限公司 | 哌嗪和哌啶衍生物 |
EP1133993A1 (en) | 2000-03-10 | 2001-09-19 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Substances for the treatment of spinal muscular atrophy |
KR20030025235A (ko) | 2000-06-07 | 2003-03-28 | 버텍스 파마슈티칼스 인코포레이티드 | 카스파제 억제제 및 이의 용도 |
US6376508B1 (en) | 2000-12-13 | 2002-04-23 | Academia Sinica | Treatments for spinal muscular atrophy |
US6982259B2 (en) | 2002-04-30 | 2006-01-03 | Schering Aktiengesellschaft | N-heterocyclic derivatives as NOS inhibitors |
RU2352568C9 (ru) | 2002-08-09 | 2009-06-27 | Астразенека Аб | [1,2,4]оксадиазолы (варианты), способ их получения, фармацевтическая композиция и способ ингибирования активации метаботропных глютаматных рецепторов-5 |
EP1581525A2 (en) | 2002-08-09 | 2005-10-05 | AstraZeneca AB | Compounds having an activity at metabotropic glutamate receptors |
WO2004014370A2 (en) | 2002-08-09 | 2004-02-19 | Astrazeneca Ab | Oxadiazoles as modulators of metabotropic glutamate receptor-5 |
AU2003280309A1 (en) * | 2002-11-11 | 2004-06-03 | Neurosearch A/S | 1,4-diazabicyclo (3,2,2)nonane derivatives, preparation and therapeutical use thereof |
CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
WO2004110351A2 (en) | 2003-05-14 | 2004-12-23 | Anadys Pharmaceuticals, Inc. | Heterocyclic compounds for treating hepatitis c virus |
WO2005007644A1 (ja) | 2003-06-27 | 2005-01-27 | Banyu Pharmaceutical Co., Ltd | ヘテロアリールオキシ含窒素飽和へテロ環誘導体 |
WO2005018547A2 (en) | 2003-08-15 | 2005-03-03 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
US7399765B2 (en) * | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
US7655657B2 (en) * | 2003-12-22 | 2010-02-02 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
WO2005077368A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
FR2868780B1 (fr) | 2004-04-13 | 2008-10-17 | Sanofi Synthelabo | Derives de la 1-amino-phthalazine, leur preparation et leur application en therapeutique |
EP1753740A2 (en) | 2004-05-21 | 2007-02-21 | Merck & Co., Inc. | Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity |
CA2571360C (en) | 2004-06-18 | 2014-11-25 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines useful in inducing cytokine biosynthesis in animals |
AR051094A1 (es) | 2004-09-20 | 2006-12-20 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa |
DK1637141T3 (da) | 2004-09-21 | 2012-02-27 | Trobio Ab | Stabiliseret proteasesammensætning omfattende en serinprotease, morpholinderivater og reversible inhibitorer af serinproteasen |
US7354944B2 (en) | 2004-10-18 | 2008-04-08 | Amgen Inc. | Thiadiazole compounds and methods of use |
WO2006045716A1 (en) * | 2004-10-20 | 2006-05-04 | Neurosearch A/S | Novel diazabicyclic aryl derivatives and their medical use |
US8501739B2 (en) * | 2005-07-04 | 2013-08-06 | High Point Pharmaceuticals, Llc | Medicaments |
AU2006323986A1 (en) * | 2005-12-06 | 2007-06-14 | Neurosearch A/S | Novel diazabicyclic aryl derivatives and their medical use |
TW200813051A (en) | 2006-05-08 | 2008-03-16 | Neurogen Corp | Substituted azaspiro derivatives |
US20080247964A1 (en) | 2006-05-08 | 2008-10-09 | Yuelian Xu | Substituted azaspiro derivatives |
JP5420398B2 (ja) | 2006-05-19 | 2014-02-19 | アッヴィ・バハマズ・リミテッド | Cns活性縮合ビシクロ複素環置換アザ二環式アルカン誘導体 |
WO2008058064A1 (en) | 2006-11-07 | 2008-05-15 | Lexicon Pharmaceuticals, Inc. | Amine-linked multicyclic compounds as inhibitors of the proline transporter |
GB0704394D0 (en) | 2007-03-07 | 2007-04-11 | Senexis Ltd | Compounds |
EP2014656A3 (en) | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | New heteocyclic h3 antagonists |
NZ585298A (en) | 2007-11-16 | 2012-08-31 | Rigel Pharmaceuticals Inc | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
CN106432213A (zh) | 2008-02-28 | 2017-02-22 | 沃泰克斯药物股份有限公司 | 作为cftr调节剂的杂芳基衍生物 |
WO2009137503A1 (en) | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Hdac inhibitors and uses thereof |
EP2288609A2 (en) | 2008-06-10 | 2011-03-02 | NeuroSearch A/S | Indolyl-pyridazinyl-diazabicyclononane derivatives in labelled and unlabelled form and their use in diagnostic methods |
GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
EP2303859A4 (en) | 2008-06-20 | 2012-08-22 | Metabolex Inc | ARYL GPR119 AGONISTS AND USES THEREOF |
CA2735593C (en) | 2008-09-03 | 2017-08-15 | Repligen Corporation | Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors |
JP2012505899A (ja) | 2008-10-16 | 2012-03-08 | シェーリング コーポレイション | アジン誘導体およびそれの使用方法 |
EP2440559B1 (en) | 2009-05-05 | 2018-01-10 | Dana-Farber Cancer Institute, Inc. | Egfr inhibitors and methods of treating disorders |
CA2773182A1 (en) | 2009-09-10 | 2011-03-17 | F. Hoffmann-La Roche Ag | Inhibitors of jak |
TWI558398B (zh) | 2009-09-22 | 2016-11-21 | 諾華公司 | 菸鹼乙醯膽鹼受體α7活化劑之用途 |
CN105906631A (zh) | 2009-11-18 | 2016-08-31 | 普莱希科公司 | 用于激酶调节的化合物和方法及其适应症 |
WO2011078143A1 (ja) | 2009-12-22 | 2011-06-30 | 塩野義製薬株式会社 | ピリミジン誘導体およびそれらを含有する医薬組成物 |
EP2542549B1 (en) | 2010-03-03 | 2016-05-11 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
WO2011130515A1 (en) * | 2010-04-14 | 2011-10-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production |
AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
WO2012022467A2 (en) | 2010-08-16 | 2012-02-23 | Santhera Pharmaceuticals (Schweiz) Ag | Novel benzoquinone derivatives and use thereof as modulators of mitochondrial function |
BR112013023813A2 (pt) | 2011-03-18 | 2016-12-13 | Novartis Ag | combinações de ativadores do receptor acetilcolina nicotínico alfa 7 e antagonistas de mglur5 para uso em dopamina induzida por discinesia na doença de parkinson |
UA113223C2 (xx) | 2012-08-13 | 2016-12-26 | Арилетинілпіримідини | |
MY174339A (en) | 2012-08-13 | 2020-04-09 | Novartis Ag | 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions |
AU2013353542B2 (en) | 2012-11-27 | 2018-04-05 | Thomas Helledays Stiftelse For Medicinsk Forskning | Pyrimidine-2,4-diamine derivatives for treatment of cancer |
US9040712B2 (en) * | 2013-01-23 | 2015-05-26 | Novartis Ag | Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions |
KR102318727B1 (ko) | 2013-07-31 | 2021-10-28 | 노파르티스 아게 | 1,4-이치환된 피리다진 유사체 및 smn-결핍-관련 상태를 치료하기 위한 그의 용도 |
-
1970
- 1970-01-01 MY MYPI2015000174A patent/MY174339A/en unknown
-
2013
- 2013-08-07 US US13/960,917 patent/US8729263B2/en active Active
- 2013-08-12 TW TW102128893A patent/TWI635083B/zh active
- 2013-08-12 JO JOP/2013/0240A patent/JO3530B1/ar active
- 2013-08-13 WO PCT/US2013/054687 patent/WO2014028459A1/en active Application Filing
- 2013-08-13 AP AP2015008242A patent/AP2015008242A0/xx unknown
- 2013-08-13 MX MX2015001892A patent/MX2015001892A/es active IP Right Grant
- 2013-08-13 NZ NZ704738A patent/NZ704738A/en unknown
- 2013-08-13 HR HRP20211957TT patent/HRP20211957T1/hr unknown
- 2013-08-13 KR KR1020227006110A patent/KR20220029764A/ko not_active Application Discontinuation
- 2013-08-13 CA CA2880273A patent/CA2880273A1/en active Pending
- 2013-08-13 HU HUE13752768A patent/HUE057007T2/hu unknown
- 2013-08-13 UA UAA201500562A patent/UA114726C2/uk unknown
- 2013-08-13 SI SI201331954T patent/SI2885288T1/sl unknown
- 2013-08-13 MA MA37834A patent/MA37834A1/fr unknown
- 2013-08-13 JP JP2015527532A patent/JP6190883B2/ja active Active
- 2013-08-13 ES ES18209821T patent/ES2950450T3/es active Active
- 2013-08-13 KR KR1020207030949A patent/KR102368439B1/ko active IP Right Grant
- 2013-08-13 PE PE2020000186A patent/PE20201165A1/es unknown
- 2013-08-13 KR KR1020157006144A patent/KR102172911B1/ko active IP Right Grant
- 2013-08-13 EA EA201590371A patent/EA032005B1/ru not_active IP Right Cessation
- 2013-08-13 BR BR112015003004-1A patent/BR112015003004B1/pt active IP Right Grant
- 2013-08-13 PT PT137527685T patent/PT2885288T/pt unknown
- 2013-08-13 SG SG11201500507UA patent/SG11201500507UA/en unknown
- 2013-08-13 LT LTEPPCT/US2013/054687T patent/LT2885288T/lt unknown
- 2013-08-13 EP EP21194692.6A patent/EP4101849A1/en active Pending
- 2013-08-13 EP EP13752768.5A patent/EP2885288B1/en active Active
- 2013-08-13 PE PE2015001214A patent/PE20151890A1/es unknown
- 2013-08-13 SG SG10201701123QA patent/SG10201701123QA/en unknown
- 2013-08-13 UY UY0001034974A patent/UY34974A/es active IP Right Grant
- 2013-08-13 DK DK13752768.5T patent/DK2885288T3/da active
- 2013-08-13 EP EP18209821.0A patent/EP3564233B1/en active Active
- 2013-08-13 PL PL13752768T patent/PL2885288T3/pl unknown
- 2013-08-13 AR ARP130102863A patent/AR092108A1/es active IP Right Grant
- 2013-08-13 CN CN201380042971.6A patent/CN104583196B/zh active Active
- 2013-08-13 MY MYPI2017000158A patent/MY176488A/en unknown
- 2013-08-13 RS RS20211507A patent/RS62692B1/sr unknown
- 2013-08-13 ES ES13752768T patent/ES2902198T3/es active Active
-
2014
- 2014-04-01 US US14/242,282 patent/US9545404B2/en active Active
-
2015
- 2015-01-23 ZA ZA2015/00531A patent/ZA201500531B/en unknown
- 2015-01-30 TN TNP2015000038A patent/TN2015000038A1/fr unknown
- 2015-02-02 IL IL237067A patent/IL237067B/en active IP Right Grant
- 2015-02-03 PH PH12015500236A patent/PH12015500236A1/en unknown
- 2015-02-11 MX MX2020010151A patent/MX2020010151A/es unknown
- 2015-02-11 CL CL2015000331A patent/CL2015000331A1/es unknown
- 2015-02-13 CU CUP2015000014A patent/CU20150014A7/es unknown
- 2015-02-13 GT GT201500030A patent/GT201500030A/es unknown
- 2015-02-13 CR CR20150078A patent/CR20150078A/es unknown
- 2015-03-13 EC ECIEPI20159862A patent/ECSP15009862A/es unknown
- 2015-09-01 HK HK15108540.1A patent/HK1207862A1/xx unknown
-
2016
- 2016-11-29 US US15/364,248 patent/US10195196B2/en active Active
-
2019
- 2019-01-02 US US16/237,907 patent/US10758533B2/en active Active
-
2020
- 2020-07-21 US US16/934,787 patent/US11229648B2/en active Active
-
2021
- 2021-12-13 US US17/644,045 patent/US20220387428A1/en active Pending
-
2022
- 2022-01-03 CY CY20221100002T patent/CY1124882T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
AR094557A1 (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn | |
AR116993A2 (es) | Compuestos heterociclos bicíclicos y sus usos en terapia | |
AR087760A1 (es) | Heterociclilaminas como inhibidores de pi3k | |
AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
AR110139A1 (es) | COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV | |
AR104025A1 (es) | Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas | |
AR090548A1 (es) | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k | |
AR106595A1 (es) | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g | |
AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
AR090945A1 (es) | Moduladores de la via del complemento y usos de los mismos | |
AR093364A1 (es) | Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso | |
AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
AR089774A1 (es) | Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
AR098853A1 (es) | Pirazoles sustituidos y usos de los mismos | |
AR091193A1 (es) | HETEROCICLOS DE 5 MIEMBROS QUE CONTIENEN NITROGENO SUSTITUIDO POR CARBOXAMIDA O SULFONAMIDA COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg | |
AR097008A1 (es) | Derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR095430A1 (es) | Compuestos de pirimidina y piridina y su uso como inhibidores de la actividad de fgfr | |
AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR088829A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
AR100418A1 (es) | Compuestos y composiciones para inducir condrogénesis | |
AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR089776A1 (es) | 5,8-dihidro-6h-pirazolo[3,4-h]quinazolinas como inhibidores de igf-1r/ir | |
AR099913A1 (es) | Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |